Abstract：Objective: To investigate the mechanisms of Jianpihuashi granule and its different components in treating diarrhea-predominant irritable bowel syndrome (IBS-D) with liver-stagnation and spleen-deficiency syndrome by examining colonic mucosal barrier function,substance P (SP),and neurokinin 1 receptor (NK1R). Methods: Ninety Sprague-Dawley rats were randomly divided into nine groups (n=10 per group):normal,model,pinaverium bromide,low-dose Jianpihuashi granule,medium-dose Jianpihuashi granule,high-dose Jianpihuashi granule,Buyi,Qushi,and Liqi groups.During the modeling phase,all experimental groups except the normal group were subjected to Senna leaf administration and restraint stress to simulate the pathological state of IBS-D.Subsequently,all groups except the normal and model groups received respective drug interventions for 14 days.Serum levels of endotoxin,D-lactic acid,and diamine oxidase (DAO) were measured using commercial kits,while SP and NK1R protein expressions were assessed via immunohistochemistry. Results: Compared to the normal group,the model group exhibited significantly elevated serum levels of endotoxin,D-lactic acid,and DAO (P<0.01).After treatment,the low-,medium-,and high-dose Jianpihuashi granule groups showed improved intestinal mucosal barrier function,with stronger effects on endotoxin and DAO levels compared to the pinaverium bromide group.The expression of SP and NK1R proteins in the model group was significantly lower than that in the normal group (P<0.01).Compared with the model group,the pinaverium bromide group showed increased SP protein expression and decreased NK1R protein expression (P<0.01),while the low-,medium-,and high-dose Jianpihuashi granule groups exhibited decreased SP and NK1R protein expression to varying degrees.The SP and NK1R protein expression levels in the Jianpihuashi granule groups were lower than those in the pinaverium bromide group (P<0.01).The Buyi,Qushi,and Liqi groups showed levels of endotoxin,DAO,SP,and NK1R related to the high-dose group,but the underlying mechanism remains unclear. Conclusion: Jianpihuashi granule improves intestinal mucosal barrier function and reduces endotoxin,D-lactic acid,and DAO levels,likely through downregulating SP and NK1R protein expression in the colon.
潘婷婷, 李喜凤, 刘玉玲, 胡楠, 杜春蕾, 杨志新, 王迎寒. 健脾化湿颗粒及不同组分对IBS-D大鼠肠黏膜屏障P物质及其受体的影响[J]. 河北医学, 2025, 31(4): 602-608.
PAN Tingting, LI Xifeng, LIU Yuling, et al. Effect of Jianpihuashi Granule and Its Different Components on Intestinal Barrier Substance P and Neurokinin 1 Receptor in IBS-D Rats. HeBei Med, 2025, 31(4): 602-608.
[1] Yuan Y,Wang X,Huang S,et al.Low-level inflammation,immunity and brain-gut axis in IBS:unraveling the complex relationships[J].Gut Microbes,2023,15(2):2263209. [2] 赵耀,刘兴山,郑薇薇.肝郁脾虚型肠易激综合征(腹泻型)中医治疗进展[J].实用中医内科杂志,2022,36(10):58-61. [3] 章海凤,曾婷,曹乾安,等.肝郁脾虚型肠易激综合征中医病证结合模型的研究进展[J].辽宁中医杂志,2022,49(5):208-212. [4] Williams C L,Villar R G,Peterson J M,et al.Stress-induced changes in intestinal transit in the rat:a model for irritable bowel syndrome[J].Gastroenterology,1988,94(3):611-621. [5] 张声生,魏玮,杨俭勤.肠易激综合征中医诊疗专家共识意见(2017)[J].中医杂志,2017,58(18):1614-1620. [6] 杜海燕.健脾化湿颗粒治疗腹泻型肠易激综合征的作用及中枢机制研究[D].承德医学院,2014. [7] 许雅青,吴月滢,李小雅,等.健脾类中药修复肠黏膜屏障损伤的研究进展[J].中国实验方剂学杂志,2021,27(14):235-241. [8] Brenner DM,Lacy BE.Antispasmodics for chronic abdominal pain:analysis of north American treatment options[J].Am Gastroenterol,2021,116(8):1587-1600. [9] Cai Y,Gong D,Xiang T,et al.Markers of intestinal barrier damage in patients with chronic insomnia disorder[J].Front Psychiatry,2024,15(1):1373462-1373462. [10] 杨焱麟,陈敏,周彦妮,等.P物质与肝郁脾虚型腹泻型肠易激综合征关系及中医药调控的研究进展[J].中华中医药学刊,2021,39(9):82-85. [11] Bradesi S,Kokkotou E,Simeonidis S,et al.The role of neurokinin 1 receptors in the maintenance of visceral hyperalgesia induced by repeated stress in rats[J].Gastroenterology,2006,130(6):1729-1742.
2025, Vol. 31 
冀公网安备13080202000786号